GlassScriptPhysician profile
Jane Sperry Chawla
NPI 1487863304
$549.47
in general payments reported to CMS, 2019-2025
12 companies · $50.25 in 2025
The $50.25 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.52 · 2021: $120 · 2022: $161 · 2023: $79.18 · 2024: $121 · 2025: $50.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.48 |
| Education | $107.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $148.15 | 2022 | |
| Seagen INC. | $96.06 | 2021 | |
| Incyte Corporation | $89.99 | 2024 | |
| Janssen Biotech, INC. | $48.17 | 2021-2025 | Talvey, Darzalex |
| Astrazeneca Pharmaceuticals LP | $32.08 | 2023 | Lynparza |
| Progenics Pharmaceuticals, INC. | $27.41 | 2025 | |
| Pfizer INC. | $26.40 | 2023 | |
| Cti Biopharma Corp. | $20.70 | 2023 | Vonjo |
| Merck Sharp & Dohme LLC | $17.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Celgene Corporation | $14.05 | 2024 | Reblozyl |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.